Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Meropenem (SM 7338) is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive agents. Meropenem is a common cause of mild transient aminotransferase elevations and can rarely result in clinically apparent, cholestatic liver injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
50 mg | In stock | $ 42.00 | |
100 mg | In stock | $ 58.00 | |
200 mg | In stock | $ 81.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | Meropenem (SM 7338) is a carbapenem antibiotic with broad spectrum of activity that is administered intravenously and used for severe bacterial infections due to sensitive agents. Meropenem is a common cause of mild transient aminotransferase elevations and can rarely result in clinically apparent, cholestatic liver injury. |
In vitro | Meropenem significantly increases the urinary excretion of valproate-glucuronide in rabbits. |
In vivo | Meropenem exhibits an antibacterial spectrum similar to that of imipenem, but demonstrates slightly lower activity against Staphylococcus aureus and Enterococcus. It possesses enhanced activity against Pseudomonas aeruginosa, all Enterobacteriaceae, and Haemophilus influenzae. Meropenem's antimicrobial efficacy against Gram-negative organisms is two to four times greater than that of imipenem, and it has a broader spectrum in comparison to all other tested agents. Furthermore, Meropenem exhibits an antagonistic effect when combined with several beta-lactam antibiotics against strain-producing type I cephalosporins. It binds most effectively to the penicillin-binding proteins 2 of Escherichia coli and Pseudomonas aeruginosa, and to the penicillin-binding protein 1 of Staphylococcus aureus. |
Kinase Assay | Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software. |
Synonyms | SM 7338 |
Molecular Weight | 383.46 |
Formula | C17H25N3O5S |
CAS No. | 96036-03-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 71 mg/mL (185.2 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: 8 mg/mL (20.86 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Meropenem 96036-03-2 Microbiology/Virology Others Antibiotic Antibacterial anaerobic parenteral neutropenia Gram-positive Inhibitor SM7338 SM 7338 DHP-1 carbapenem β-lactamases Bacterial Gram-negative SM-7338 inhibit inhibitor